Clinical Trial Update: An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options

View source ↗

Summary

Regulatory approval for marketing of adefovir dipivoxil for lamivudine-resistant chronic hepatitis B, expanding treatment options for patients with limited choi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Hepsera (adefovir dipivoxil)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis B | Status: APPROVED_FOR_MARKETING